Seung Min Kim

ORCID: 0000-0002-4384-9640 · 1 paper in corpus

article 2025

O-251 Treatment of endometriosis-associated pain with merigolix, an oral GnRH receptor antagonist: results from a phase 2a, randomized, double-blind, placebo-controlled study

·doi:10.1093/humrep/deaf097.251

Abstract Study question Does merigolix administered orally once daily for 12 weeks reduce the pain symptoms in women with endometriosis-associated pains (EAP)? Summary answer Merigolix was effective in improving endometriosis-associated pai…